Merck First-Quarter 2026 Financial Results and Strategic Milestones

These documents outline Merck & Co.’s first-quarter 2026 financial performance, highlighting a 5% increase in total worldwide sales to $16.3 billion. Success was primarily fueled by significant growth in the oncology and animal health sectors, with the cancer drug KEYTRUDA remaining a dominant revenue driver. Despite this growth, the company reported a net loss due to a substantial $9 billion charge from its acquisition of Cidara Therapeutics. The reports also detail the strategic expansion of their medical pipeline through the planned purchase of Terns Pharmaceuticals and various FDA approvals for HIV and dermatitis treatments. Management remains optimistic, raising their full-year revenue guidance while anticipating over twenty new blockbuster growth drivers by the mid-2030s. Together, these sources provide a comprehensive look at the organization’s clinical milestones and long-term fiscal strategy.